Novartis AG

Novartis AG

Novartis AG

Overview
Date Founded

1996

Headquarters

Lichtstrasse 35, Basel, 4056, CHE

Type of Company

Public

Employees (Worldwide)

125K

Industries

Pharmaceuticals
Hospitals & Patient Services
Wholesale: Consumer Non-Durables/Sundries
Biotechnology

Company Description

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Contact Data
Trying to get in touch with decision makers at Novartis AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Group General Counsel of Novartis

Chief Medical Officer

Chief Digital Officer

Chief Executive Officer, Novartis Oncology

Interim Division Head & Chief Executive Officer, Novartis Pharmaceuticals

Chief Executive Officer, Alcon

Head of Novartis Business Services (Nbs)

Group Head of Global Health & Corporate Responsibility

Board of Directors

Former Chief Operating Officer at Novartis AG

Professional at Novartis AG

Group Chief Executive Officer at Standard Chartered PLC

Chairman, Human Oncology & Pathogenesis Program at Memorial Sloan-Kettering Cancer Center

Professional at Novartis AG

Senior Associate Dean for University Affairs at Harvard University - Harvard Business School

President & Chief Executive Officer at Koninklijke Philips NV

Partner at Lenz & Staehelin AG

Executive Vice President Head of Strategic Business Units, Marketing, Sales & Nespresso at Nestlé SA

Dean at Duke University - School of Medicine

Paths to Novartis AG
Potential Connections via
Relationship Science
You
Novartis AG
Owners & Shareholders
Details Hidden

Dodge & Cox's investment decisions are made by a team of seasoned investment professionals based on key fundamental factors that they believe determine investment value over the long term. The firm's investment analysts operate from a single location to foster communication and collaboration and each investment idea is subject to committee review for both its merits as a specific investment and its role in the overall portfolio. Their approach stresses an evaluation of risk relative to opportunity and we seek investments that we believe are undervalued by the market. Fundamental bottom-up research, a rigorous valuation discipline and a long-term investment horizon are central to Dodge & Cox's investment philosophy.

Details Hidden

NBIM is an active, conservative manager with a long-term outlook that aims to get the highest possible return on the Government Pension Fund Global within the investment mandate set by the Ministry of Finance, which owns the fund on behalf of the Norwegian people. The ministry determines the fund's investment strategy, following advice from among others, NBIM and discussions in Parliament. The firm's mandate defines the investment universe and the fund's strategic reference index. The Ministry of Finance has on a regular basis transferred capital to the fund from the Norwegian state's petroleum revenues. The fund's capital is invested abroad, to avoid overheating the Norwegian economy and to shield it from the effects of oil price fluctuations. The fund invests in international equity and fixed-income markets and real estate. It is invested in most markets, countries and currencies to achieve broad exposure to global economic growth. The investments are to produce a high long-term return. NBIM aims to achieve this this with an acceptable level of risk, as a responsible investor and through an efficient organization.

Details Hidden

Wellington Management's investment services rely on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macroanalysts, quantitative analysts and technical analysts. Wellington Management's portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team's investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Recent Transactions
Details Hidden

Novartis AG purchases Ifm Tre, Inc. from Abingworth LLP, Atlas Venture, Inc., IFM Therapeutics LLC

Details Hidden

purchases Alcon, Inc. from Novartis AG

Details Hidden

Novartis AG, AveXis, Inc. purchase Astrazeneca Plc /Longmont Manufacturing Operations from AstraZeneca Plc

Transaction Advisors
Legal Advisor

Advised onNovartis AG purchases Chiron Corp.

Accountant

Advised onNovartis AG purchases Chiron Corp.

Investment Advisor

Advised onNovartis AG purchases Alcon, Inc. from Nestlé SA

Legal Advisor

Advised onNovartis International AG, Novartis AG purchase AveXis, Inc.

Co-Chair, Corporate Group

Advised onNovartis AG purchases Alcon, Inc. from Nestlé SA

Legal Advisor

Advised onEli Lilly & Company purchases Elanco Tiergesundheit AG from Novartis AG

Advisors & Consultants
Consultant

The Energy Project energizes people and transforms companies, offering a detailed blueprint for fueling a fully engaged workforce. Drawing on the multidisciplinary science of high performance, we do this at three levels: We train people to perform sustainably at the highest levels by more skillfully managing their energy across four dimensions: physical, emotional, mental and spiritual to develop actionable strategies that help them to become more energized, focused and productive. We teach leaders to become Chief Energy Officers, who mobilize, inspire, focus, direct and regularly recharge the energy of those they lead. We partner with companies to help them better meet the core needs of their employees, so they’re freed, fueled and inspired to bring the best of themselves to work every day. Demand is exceeding our capacity. Time is the resource we’ve traditionally relied on to get more done. The problem with time is that it’s finite, and most of us no longer have additional hours left to invest at work. Energy, by contrast, can be expanded and regularly renewed. Drawing on the multidisciplinary science of high performance, The Energy Project has developed a set of simple principles and highly actionable practices for more effectively managing energy to drive higher levels of engagement, productivity, and innovation. Our clients range from companies such as Google, Coca Cola, Target, Sony, Ernst & Young, and Pfizer to organizations such as the Los Angeles Police Department, the Cleveland Clinic, Kipp Schools and many others.

Legal Advisor

Shareholder at Greenberg Traurig LLP

Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Legal Advisor

Partner at Winston & Strawn LLP

Clients

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Key Stats and Financials As of 2018
Market Capitalization
$190B
Total Enterprise Value
$213B
Earnings Per Share
$5.32
Revenue
$50.8B
Total Equity
$77.6B
Net Profit
$12.3B
EBITDAMargin
29.1%
Enterprise Value Sales
4.19x
Enterprise Value EBITDAOperating
14.41x
TEVNet Income
17.26x
Debt TEV
0.15x
Total Debt
$31.6B
EBITDA
$14.8B
Three Year Compounded Annual Growth Rate Of Revenue
2.18%
Five Year Compounded Annual Growth Rate Of Revenue
-1.02%
Investments
Details Hidden

SomaLogic, Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at your institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO.

Details Hidden

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded on December 16, 2014 and is headquartered in San Diego, CA.

Details Hidden

Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

Investors
Details Hidden

Co-Founder at Allos Ventures LLC

Suppliers
AptarGroup, Inc. Paper Products | Crystal Lake, IL

AptarGroup, Inc. develops, manufactures and sales of consumer product dispensing systems. It operates through the following business segments : Beauty & Home, Pharma, and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sell dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Alexandria Real Estate Equities, Inc. Real Estate Investment Trusts | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Veeva Systems, Inc. Other Business & Consulting Services | PLEASANTON, CA

Veeva Systems, Inc. engages in the provision of industry-specific, cloud-based software solutions for the life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage a regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Novartis AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Novartis AG's profile does not indicate a business or promotional relationship of any kind between RelSci and Novartis AG.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/novartis-ag-258830
  • https://relationshipscience.com/organization/novartis-ag-258830